Advertisement

Topics

Nightstar gets rights to preclinical ophthalmic program from Oxford University Innovation

14:40 EST 8 Nov 2017 | Elsevier Business Intelligence

Oxford University Innovation Ltd. licensed Nightstar Therapeutics Ltd. exclusive worldwide rights to a preclinical gene thera...

Original Article: Nightstar gets rights to preclinical ophthalmic program from Oxford University Innovation

NEXT ARTICLE

More From BioPortfolio on "Nightstar gets rights to preclinical ophthalmic program from Oxford University Innovation"

Quick Search
Advertisement
 

Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...